Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2022 | Session highlights: difficult scenarios in the myeloproliferative spectrum

In this video, Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, gives a detailed overview of a session held at BSH 2022, which focused on difficult scenarios in the myeloproliferative spectrum. Prof. Harrison first discusses a presentation held by Prof. Adam Mead on new data for blast-phase myeloproliferative neoplasms (MPN-BP) and the importance of this data for the future treatment of MPNs. Following this, Prof. Harrison discusses another presentation held by Dr Dan Wiseman which focused on the treatment and management of chronic myelomonocytic leukemia (CMML), and concludes by discussing some recent research investigating the management of patients diagnosed with MPNs before the age of 25, and the importance of obtaining real-world data in these scenarios. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.

Disclosures

Research funding: Celgene, Constellation, Novartis
Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra